Journal
MAYO CLINIC PROCEEDINGS
Volume 84, Issue 9, Pages 787-794Publisher
MAYO CLINIC PROCEEDINGS
DOI: 10.4065/84.9.787
Keywords
-
Categories
Funding
- Merck Research Laboratories, North Wales, PA
- National Institutes of Health [AR30582]
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER
Ask authors/readers for more resources
OBJECTIVE: To conduct a population-based study to assess health care utilization (HCU) and costs associated with herpes zoster (HZ) and Its complications, Including postherpetic neuralgia (PHN) and nonpain complications, In adults aged 22 years and older. PATIENTS AND METHODS: Medical record data on HCU were abstracted for all confirmed new cases of HZ from January 1, 1996, through December 31, 2001, among residents of Olmsted County, Minnesota. Herpes zoster-related costs were estimated by applying the Medicare Payment Fee Schedule to health care encounters and mean wholesale prices to medications. All costs were adjusted to 2006 US dollars using the medical care component of the Consumer Price Index. RESULTS: The HCU and cost of the 1669 Incident HZ cases varied, depending on the complications Involved. From 3 weeks before to I year after Initial diagnosis, there were a mean of 1.8 outpatient visits and 3.1 prescribed medications at a cost of $720 for cases without PHN or nonpain complications compared with 7.5 outpatient visits and 14.7 prescribed medications at a cost of $3998 when complications, PHN, or nonpain complications were present. CONCLUSION: The annual medical care cost of treating Incident HZ cases In the United States, extrapolated from the results of this study In Olmsted County, Is estimated at $1.1 billion. Most of the costs are for the care of Immunocompetent adults with HZ, especially among those 50 years and older.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available